Skip to main content
. 2019 Feb 10;2019:3561501. doi: 10.1155/2019/3561501

Table 2.

Multivariate predictors of chemotherapy receipt in nonmetastatic uterine LMS.

Variable OR 95% CI P
Year of diagnosis
Per year increase 1.16 1.13–1.20 <0.0001

Age at diagnosis, y
18–39 Ref
40–49 0.93 0.67–1.31 0.6927
50–64 0.93 0.67–1.29 0.6537
65+ 0.60 0.38–0.94 0.0264

Race
White Ref
African American 0.80 0.63–1.02 0.0727
Other 1.09 0.78–1.53 0.5965

Hispanic
Yes 1.34 0.94–1.91 0.1112
No Ref

Comorbidities (Charlson/Deyo score)
0 Ref
1 0.93 0.73–1.18 0.5332
2 0.72 0.37–1.41 0.3381

Insurance status
Private Ref
Medicare 0.59 0.42–0.84 0.0030
Medicaid 1.06 0.77–1.48 0.7062
None 0.92 0.64–1.30 0.6265
Other government 2.42 1.04–5.61 0.0400

Education (% no high school diploma)
≥21 0.68 0.48–0.97 0.0354
13–20.9 0.58 0.43–0.79 0.0005
7–12.9 0.86 0.68–1.09 0.2143
<7 Ref

Median household income ($)
<38,000 1.49 1.04–2.13 0.0282
38,000–47,999 1.42 1.05–1.92 0.0239
48,000–62,999 1.37 1.07–1.75 0.0117
>63,000 Ref

Location of patient
Large metropolitan Ref
Small metropolitan 0.92 0.73–1.15 0.4570
Suburban 1.00 0.73–1.39 0.9764
Rural 0.69 0.43–1.10 0.1146

Hospital volume (cases per year)
0.09 Ref
0.18–0.27 1.00 0.62–1.61 0.9964
0.36–0.55 1.18 0.74–1.87 0.4912
0.64–7.27 1.27 0.82–1.98 0.2812

Regional lymph nodes positive
Yes 3.83 1.81–8.09 0.0004
No Ref

Stage
I 0.32 0.25–0.41 <0.0001
II 0.38 0.26–0.56 <0.0001
III Ref

Hormone therapy
Yes 0.72 0.30–1.70 0.4473
No Ref

Radiation
Yes 1.45 1.17–1.79 0.0006
No Ref

Oophorectomy
Yes 0.92 0.72–1.19 0.5395
No Ref